Cargando…
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
INTRODUCTION: Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a prospectively designed 24-week open-label, single-a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656719/ https://www.ncbi.nlm.nih.gov/pubmed/28918581 http://dx.doi.org/10.1007/s12325-017-0613-9 |
_version_ | 1783273747168362496 |
---|---|
author | Guerdjikova, Anna I. Walsh, Brandon Shan, Kevin Halseth, Amy E. Dunayevich, Eduardo McElroy, Susan L. |
author_facet | Guerdjikova, Anna I. Walsh, Brandon Shan, Kevin Halseth, Amy E. Dunayevich, Eduardo McElroy, Susan L. |
author_sort | Guerdjikova, Anna I. |
collection | PubMed |
description | INTRODUCTION: Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a prospectively designed 24-week open-label, single-arm, single-site trial of 25 women with MDD and overweight/obesity, NB reduced weight and depressive symptoms. METHODS: This post hoc analysis investigated the relationship between change in self-reported binge eating behavior (evaluated with the Binge Eating Scale [BES]) and changes in weight, control of eating, and depressive symptoms. RESULTS: At baseline, 91% of subjects had moderate or severe BES scores, suggesting BED. BES scores were significantly improved from week 4, and by week 24, 83% reported “little or no problem.” Improvement in BES scores correlated with improvement in depressive symptoms and control of eating. CONCLUSION: NB may be effective in reducing binge eating symptoms associated with MDD and overweight/obesity. Evaluation of NB in BED appears warranted. FUNDING: Orexigen Therapeutics, Inc. |
format | Online Article Text |
id | pubmed-5656719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-56567192017-11-01 Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study Guerdjikova, Anna I. Walsh, Brandon Shan, Kevin Halseth, Amy E. Dunayevich, Eduardo McElroy, Susan L. Adv Ther Original Research INTRODUCTION: Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a prospectively designed 24-week open-label, single-arm, single-site trial of 25 women with MDD and overweight/obesity, NB reduced weight and depressive symptoms. METHODS: This post hoc analysis investigated the relationship between change in self-reported binge eating behavior (evaluated with the Binge Eating Scale [BES]) and changes in weight, control of eating, and depressive symptoms. RESULTS: At baseline, 91% of subjects had moderate or severe BES scores, suggesting BED. BES scores were significantly improved from week 4, and by week 24, 83% reported “little or no problem.” Improvement in BES scores correlated with improvement in depressive symptoms and control of eating. CONCLUSION: NB may be effective in reducing binge eating symptoms associated with MDD and overweight/obesity. Evaluation of NB in BED appears warranted. FUNDING: Orexigen Therapeutics, Inc. Springer Healthcare 2017-09-16 2017 /pmc/articles/PMC5656719/ /pubmed/28918581 http://dx.doi.org/10.1007/s12325-017-0613-9 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Guerdjikova, Anna I. Walsh, Brandon Shan, Kevin Halseth, Amy E. Dunayevich, Eduardo McElroy, Susan L. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title | Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title_full | Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title_fullStr | Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title_full_unstemmed | Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title_short | Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study |
title_sort | concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656719/ https://www.ncbi.nlm.nih.gov/pubmed/28918581 http://dx.doi.org/10.1007/s12325-017-0613-9 |
work_keys_str_mv | AT guerdjikovaannai concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy AT walshbrandon concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy AT shankevin concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy AT halsethamye concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy AT dunayevicheduardo concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy AT mcelroysusanl concurrentimprovementinbothbingeeatinganddepressivesymptomswithnaltrexonebupropiontherapyinoverweightorobesesubjectswithmajordepressivedisorderinanopenlabeluncontrolledstudy |